Method of treating constipation-predominant irritable bowel syndrome
Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.
1. A method of treating constipation-predominant irritable bowel syndrome (C-IBS), comprising administering an effective amount of a selective inhibitor of methanogenesis to the distal gut of a human patient in need thereof, wherein:
the C-IBS is characterized by elevated intestinal methane levels and
the selective inhibitor of methanogenesis is a HMG-CoA reductase inhibitor.
2. The method of claim 1 , wherein the method inhibits the growth of methanogenic bacteria in the human patient.
3. The method of claim 1 , wherein the method reduces the partial pressure of methane in the human patient's intestines.
4. The method of claim 1 , wherein the method reduces the partial pressure of methane in the human patient's intestines as assessed by methane breath testing.
5. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is administered enterally.
6. The method of claim 5 , wherein the HMG-CoA reductase inhibitor is administered orally.